Practical Considerations for AI in Community Oncology

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.

AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.

HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.